Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2017 | (b) 2018 | (c) 2019 | (d) 2020 | (e) 2021 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 561,378,936 | 604,363,420 | 629,412,126 | 726,297,460 | 702,430,542 | 3,223,882,484 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 561,378,936 | 604,363,420 | 629,412,126 | 726,297,460 | 702,430,542 | 3,223,882,484 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | 0 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 3,223,882,484 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2017 | (b) 2018 | (c) 2019 | (d) 2020 | (e) 2021 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 561,378,936 | 604,363,420 | 629,412,126 | 726,297,460 | 702,430,542 | 3,223,882,484 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 9,629,978 | 101,304,972 | 52,614,894 | 113,415,703 | 44,851,524 | 321,817,071 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 23,432,437 | 14,052,058 | 14,915,439 | 7,706,225 | 13,596,972 | 73,703,131 |
| 11 | Total support. Add lines 7 through 10 | 3,619,776,480 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2017 | (b) 2018 | (c) 2019 | (d) 2020 | (e) 2021 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2017 | (b) 2018 | (c) 2019 | (d) 2020 | (e) 2021 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2021 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2021 |
(iii) Distributable Amount for 2021 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2021 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2021 (reasonable cause required-- explain in Part VI). See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2021: | ||||
| a From 2016....... | ||||
| b From 2017....... | ||||
| c From 2018....... | ||||
| d From 2019....... | ||||
| e From 2020....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2021 distributable amount | ||||
|
i
Carryover from 2016 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2021 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2021 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2021, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2021. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2022. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2017..... | ||||
| b Excess from 2018..... | ||||
| c Excess from 2019..... | ||||
| d Excess from 2020..... | ||||
| e Excess from 2021..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|---|
| Schedule A, Part II, Line 10 Other Income | DESCRIPTION - PARKING LOT REVENUE, COLUMN A - 5813650.0, COLUMN B - 6073362.0, COLUMN C - 3877282.0, COLUMN D - 3167144.0, COLUMN E - 4721708.0, COLUMN F - 23653146.0; DESCRIPTION - FOOD SERVICE REVENUE, COLUMN A - 4038106.0, COLUMN B - 4291088.0, COLUMN C - 2743883.0, COLUMN D - 2516332.0, COLUMN E - 3633966.0, COLUMN F - 17223375.0; DESCRIPTION - SURPLUS CAPITAL DISTRIBUTION, COLUMN A - 1073088.0, COLUMN B - 1113069.0, COLUMN C - 647635.0, COLUMN D - 698598.0, COLUMN E - 1820768.0, COLUMN F - 5353158.0; DESCRIPTION - MISCELLANOUS REVENUE, COLUMN A - 11584400.0, COLUMN B - 1661376.0, COLUMN C - 7376177.0, COLUMN D - 1067783.0, COLUMN E - 2815275.0, COLUMN F - 24505011.0; DESCRIPTION - FUNDRAISING EVENTS, COLUMN A - 923193.0, COLUMN B - 913163.0, COLUMN C - 270462.0, COLUMN D - 256368.0, COLUMN E - 605255.0, COLUMN F - 2968441.0; |
| Software ID: | 21014044 |
| Software Version: | 2021v4.2 |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| Form 990, Part I, Line 1 | THE MISSION OF DANA-FARBER CANCER INSTITUTE, INC. (DFCI) IS TO PROVIDE EXPERT, COMPASSIONATE, AND EQUITABLE CARE TO CHILDREN, ADULTS, AND THEIR FAMILIES, WHILE ADVANCING THE UNDERSTANDING, DIAGNOSIS, TREATMENT, CURE, AND PREVENTION OF CANCER AND RELATED DISEASES. WE TRAIN NEW GENERATIONS OF CLINICIANS AND SCIENTISTS, DISSEMINATE INNOVATIVE PATIENT THERAPIES AND SCIENTIFIC DISCOVERIES AROUND THE WORLD, AND REDUCE THE IMPACT OF CANCER, WHILE AT ALL TIMES MAINTAINING A FOCUS ON THOSE COMMUNITIES THAT HAVE BEEN HISTORICALLY MARGINALIZED. |
| Form 990, Part III, Line 1 | THE MISSION OF DANA-FARBER CANCER INSTITUTE, INC. (DFCI) IS TO PROVIDE EXPERT, COMPASSIONATE, AND EQUITABLE CARE TO CHILDREN, ADULTS, AND THEIR FAMILIES, WHILE ADVANCING THE UNDERSTANDING, DIAGNOSIS, TREATMENT, CURE, AND PREVENTION OF CANCER AND RELATED DISEASES. WE TRAIN NEW GENERATIONS OF CLINICIANS AND SCIENTISTS, DISSEMINATE INNOVATIVE PATIENT THERAPIES AND SCIENTIFIC DISCOVERIES AROUND THE WORLD, AND REDUCE THE IMPACT OF CANCER, WHILE AT ALL TIMES MAINTAINING A FOCUS ON THOSE COMMUNITIES THAT HAVE BEEN HISTORICALLY MARGINALIZED. |
| Form 990, Part III, Line 4a | CLINICAL CARE As one of the leading cancer centers in the world, Dana-Farber Cancer Institute provides compassionate, comprehensive, and personalized care to adults and children with cancer, blood disorders, and related diseases. In fiscal year 2022, our expert clinicians and caregivers at our specialized treatment centers worked together to deliver the latest therapies to our patients through 1,288 inpatient admissions, 368,976 outpatient MD visits, and 201,477 infusion treatments. Since its founding in 1947 by Sidney Farber, MD, Dana-Farber has followed his vision for a cancer center that is just as dedicated to discoveries in cancer research as it is to delivering expert, compassionate care. Our Institute is a founding member of Dana-Farber/Harvard Cancer Center and one of 53 NCI-designated Comprehensive Cancer Centers in the U.S. We are the only hospital ranked in the top four nationally by U.S News and World Report in both adult and pediatric cancer care. In 2022, we offered more than 1,100 clinical trials. |
| Form 990, Part III, Line 4b | RESEARCH Scientific work at Dana-Farber is based on the premise that basic and clinical investigation are complementary and reinforcing activities. To encourage this cross-pollination of ideas, the Institute has developed an organizational framework that fosters collaborations among investigators from different disciplines. The result is an intense scientific impact on a group of diseases that continue to represent one of humanity's greatest health challenges. Some recent advances include: Novel "conjugate" therapy outperforms standard treatment for recurrent ovarian cancer: In an international clinical trial co-led by Dana-Farber investigators, a therapy made by fusing an antibody to a drug molecule produced substantially better results than standard therapy in patients with recurrent ovarian cancer resistant to platinum-based chemotherapy. Study finds Racial inequities in access to opioids among older patients with terminal cancer: Older Black and Hispanic patients with advanced cancer are less likely than White patients to receive pain-relieving opioid medicines in the last weeks of life, a study by Dana-Farber investigators found. Genetic variations increase risk of adverse side effects from cancer immunotherapy: Research by Dana-Farber scientists identified, for the first time, genetic alterations that place patients at high risk for complications from immune checkpoint inhibitor drugs. Study offers encouragement for younger women with breast cancer hoping to pursue pregnancy: A Dana-Farber-led study of patients with breast cancer who were 42 or younger found that those who paused endocrine therapy to try to become pregnant had similar short-term rates of breast cancer recurrence as women who did not pause treatment for pregnancy. Most participants who paused treatment went on to conceive and delivery healthy babies. Patients with cancer and a suppressed immune system at high risk for severe COVID if treated with systemic drug therapies: Patients with cancer and a weakened immune system who are treated with immunotherapies tend to fare far worse from COVID-19 than those who haven't received such therapies in the three months before their COVID diagnosis, a study led by Dana-Farber investigators found. Digital platform quickly matches patients with cancer to clinical trials of targeted therapy: MatchMiner, a computer-based platform developed at Dana-Farber, makes it faster and easier to match patients to clinical trials of targeted therapies for their specific type of cancer. Three-drug combination slows progression of advanced kidney cancer: Adding a drug known as a targeted kinase inhibitor to a two-drug immunotherapy regimen showed the progression of advanced kidney cancer in previously untreated patients, research by Dana-Farber scientists found. Online tool identifies people likely to benefit from genetic testing for inherited cancer risk: An online tool - PREMMplus - developed at Dana-Farber can rapidly identify people who should be tested for inherited genetic changes that raise the risk of developing certain cancers, a study showed. Scientists identify a key gene activated in most cancer types: Scientists at Dana-Farber and the Broad Institute of MIT and Harvard discovered that the gene FOXR2, which is normally idle in most tissues, is activated in at least 70% of cancer types, making it a promising target for future therapies. Genomic profiling of pediatric tumors can enhance patients' care: By doing a molecular analysis of hundreds of tumors from children with cancer, Dana-Farber scientists found that the vast majority had clinically significant genetic alterations - information that can improve diagnosis and, potentially, treatment. Targeted drug achieves strong response rate in lung tumor with KRAS gene mutation: Nearly 43% of patients with non-small cell lung cancer harboring a specific mutation in the KRAS gene responded to the targeted agent adagrasib, which also showed activity against tumors that had spread from the lungs to the brain, a study led by Dana-Farber investigators found. Race and poverty linked to worse outcomes in children with high-risk neuroblastoma: Children with high-risk neuroblastoma had worse outcomes if they were from historically marginalized or lower-income populations or were on public rather than private insurance, investigators at the Dana-Farber/Boston Children's Cancer and Blood Disorders Center found. |
| Form 990, Part III, Line 4c | COMMUNITY BENEFITS THE ROLE OF DANA-FARBER'S COMMUNITY BENEFITS OFFICE IS TO SUPPORT THE INSTITUTE'S GOAL TO REDUCE CANCER RISK AMONG MEDICALLY UNDERSERVED POPULATIONS. WE WORK WITH CITY AND STATE HEALTH DEPARTMENTS, COMMUNITY PARTNERS, AND BOSTON-BASED COALITIONS TO ASSESS AND MONITOR THE NEEDS OF LOCAL RESIDENTS WITH RESPECT TO CANCER CONTROL. IN COLLABORATION WITH STAFF THROUGHOUT DANA-FARBER, WE SERVE AS A BRIDGE WITH COMMUNITY ORGANIZATIONS AND ESTABLISH EVIDENCE-BASED AND SUSTAINABLE OUTREACH PROGRAMS. WE ARE ON THE FRONT LINES OF SUPPORTING AND COLLABORATING ON PROGRAMS DESIGNED TO ELIMINATE DISPARITIES IN BREAST, COLON, AND SKIN CANCER; EDUCATE DIVERSE POPULATIONS ABOUT TOBACCO CESSATION, HUMAN PAPILLOMAVIRUS (HPV) PREVENTION AND SCREENING; AND STRENGTHEN THE SUPPORT SYSTEM FOR MEDICALLY UNDERSERVED POPULATIONS. IN SHORT, WE ARE COMMITTED TO MAKING DANA-FARBER'S CARE AND RESEARCH FINDINGS MORE ACCESSIBLE TO EVERYONE WITHIN AND OUTSIDE ITS WALLS. IN FY 2022: A TOTAL OF 1,333 INDIVIDUALS WERE REACHED THROUGH 21 COMMUNITY EDUCATION, OUTREACH, AND SCREENING EVENTS. PROGRAM VOLUMES HAVE CONTINUED TO BE IMPACTED BY THE ONGOING COVID-19 PANDEMIC. THE COMMUNITY BENEFITS OFFICE HAS CONTINUED TO PIVOT TO ADAPT TO CHALLENGES RELATED TO THE ONGOING COVID-19 PANDEMIC. IN PARTICULAR, THE COMMUNITY BENEFITS OFFICE CONTINUES TO PROVIDE EDUCATION VIRTUALLY IN PARTNERSHIP WITH UNION CAPITAL BOSTON (UCB) AND OTHER COMMUNITY PARTNERS AND IS WORKING TO EXPAND AND STRENGTHEN DIGITAL EDUCATION AND OUTREACH STRATEGIES. FY22 PROGRAMMATIC HIGHLIGHTS ARE AS FOLLOWS: DANA-FARBER SUCCESSFULLY EXPANDED NEW COMMUNITY-FACING PATIENT NAVIGATION PROGRAM TO THE THORACIC CENTER, WITH PLANS TO EMBED THIS MODEL INTO ALL MAJOR CLINICAL AREAS AT DANA-FARBER. DANA-FARBER'S MAMMOGRAPHY SERVICES PROVIDED 1,914 MAMMOGRAMS ON THE VAN AND AT THE MAMMOGRAPHY SUITE AT WHITTIER STREET HEALTH CENTER IN ROXBURY. DANA-FARBER'S SUN SAFETY PROGRAM PROVIDED 16 IN-PERSON SUN SAFETY SCREENING EVENTS WITH ADDED HEALTH AND SAFETY MEASURES AND APPROVAL FROM LOCAL HEALTH DEPARTMENTS. 801 PARTICIPANTS WERE SCREENED BY A DERMATOLOGIST AND 182 PEOPLE WERE REFERRED FOR FOLLOW-UP APPOINTMENTS. 71 PARTICIPANTS WERE REFERRED FOR A BIOPSY. DANA-FARBER'S TOBACCO TREATMENT PROGRAM RECEIVED 67 REFERRALS AND PROVIDED 60 INDIVIDUAL TOBACCO CESSATION COUNSELING SESSIONS TO 20 PATIENTS. 19 PARTICIPANTS WERE ABLE TO REDUCE THEIR TOTAL NUMBER OF CIGARETTES SMOKED PER DAY, AND 7 OF THESE REPORTED BEING ABLE TO QUIT COMPLETELY. THE TOBACCO TREATMENT PROGRAM CONTINUED TO PROVIDE FINANCIAL INCENTIVES FOR PARTICIPANTS ENROLLED IN THE PROGRAM. STOP AND SHOP GIFT CARDS WERE PROVIDED AFTER EACH COUNSELING SESSION TO ENCOURAGE INDIVIDUALS TO REDUCE THEIR TOBACCO USAGE AND QUIT SMOKING. DANA-FARBER CONTINUED IT'S PARTNERSHIP WITH TEAM MAUREEN TO LEAD THE STATEWIDE MASSACHUSETTS HPV COALITION. THIS YEAR, THE COALITION'S ORAL HPV TASK FORCE CONTINUED TO PROVIDE HPV EDUCATION TO ORAL HEALTH PROVIDERS AND DISTRIBUTED THE SECOND EDITION OF THEIR DENTAL TOOLKIT FOR PROVIDERS AND PATIENTS IN 7 LANGUAGES. ADDITIONALLY, DANA-FARBER PLAYED A LEADING ROLE IN ORGANIZING THE ANNUAL HPV-RELATED CANCER SUMMIT, WHICH ENGAGED APPROXIMATELY 105 MEDICAL AND DENTAL PROVIDERS, PUBLIC HEALTH PROFESSIONALS AND COMMUNITY ADVOCATES ON THE LATEST HPV RESEARCH AND BEST PRACTICES. DANA-FARBER PROVIDED SINGLE-YEAR DETERMINATION OF NEED COMMUNITY-CLINICAL LINKAGES FUNDING TO EIGHT NON-PROFIT ORGANIZATIONS IN GREATER BOSTON TO IMPROVE LINKAGES TO HEALTH AND SUPPORT SERVICES. DANA-FARBER LAUNCHED AND EVALUATED THE FIRST YEAR OF DANA-FARBER'S MULTI-YEAR SYSTEMS LEVEL FUNDING, WHICH WAS AWARDED TO FOUR NON-PROFIT ORGANIZATIONS IN GREATER BOSTON TO ADDRESS ENVIRONMENTAL JUSTICE, FOOD INSECURITY, AND CHILD HOMELESSNESS. DANA-FARBER COMMITTED $500K TO THE HEALTHY RETAIL COMMERCE FUND TO SUPPORT HEALTHY FOOD ACCESS AND $250K TO THE BOSTON LOCAL INITIATIVES SUPPORT CORPORATION (LISC BOSTON) SMALL BUSINESS GROWTH FUND TO SUPPORT ECONOMIC EMPOWERMENT AND GROW BUSINESSES OWNED BY BLACK, LATINO, AND INDIGENOUS ENTREPRENEURS AND OTHER PEOPLE OF COLOR. THIS BUILDS ON DANA-FARBER'S PREVIOUS $1M INVESTMENT IN THE HEALTHY NEIGHBORHOOD EQUITY FUND II MADE IN FY21 TO ADDRESS HOUSING NEEDS IN GREATER BOSTON. DANA-FARBER PARTNERED WITH UNION CAPITAL BOSTON AND DF/HCC TO HOST FOUR CANCER AWARENESS RESOURCE NIGHTS FOCUSED ON BREAST CANCER SCREENING, TOBACCO CESSATION, HPV VACCINE, AND CANCER SURVIVORSHIP, ENGAGING OVER 500 RESIDENTS VIRTUALLY. THESE EVENTS FEATURED AN EDUCATION SESSION ON A CANCER-RELATED TOPIC, SURVIVOR TESTIMONY, AND QA SESSIONS WITH AUDIENCE MEMBERS. DANA-FARBER DEVELOPED A NEW CANCER-FOCUSED COMMUNITY HEALTH NEEDS ASSESSMENT AND IMPLEMENTATION PLAN FOR THE 2022-2025 TRIENNIAL CYCLE AND CONTINUED TO PLAY A LEADERSHIP ROLE IN THE BOSTON CHNA/CHIP COLLABORATIVE. |
| Form 990, Part VI, Line 2 Family/business relationships amongst interested persons | RICHARD LUBIN, CHRISTOPHER HADLEY, AND JANE BROCK-WILSON - Business relationship, JOSH BEKENSTEIN, ANDREW KAPLAN, AND NANCY LOTANE - Business relationship, PHILLIP GROSS AND DEMOND MARTIN - Business relationship, ANDREW JANOWER AND MICHAEL EISENSON - Business relationship, BRIAN KNEZ AND JESSICA KNEZ - Family relationship, JOHN O'CONNOR AND LAURA SEN - Family relationship |
| Form 990, Part VI, Line 11b Review of form 990 by governing body | THE DANA-FARBER CANCER INSTITUTE TAX DEPARTMENT PROVIDES ALL FINANCIAL ANALYSIS AND OTHER INFORMATION TO BE INCLUDED ON THE TAX RETURN TO ITS EXTERNAL TAX PREPARER, ERNST YOUNG LLP, WHICH PREPARES THE DRAFT RETURN. THE DRAFT RETURN IS THEN REVIEWED BY THE DFCI TAX MANAGER, AS WELL AS THE DFCI OFFICE OF GENERAL COUNSEL AND SENIOR MANAGEMENT, BEFORE IT IS SUBMITTED FOR DFCI AUDIT COMMITTEE REVIEW. AFTER THE AUDIT COMMITTEE REVIEWS THE TAX RETURN, AN ELECTRONIC MESSAGE IS SENT TO ALL GOVERNING BOARD MEMBERS WITH A SECURE LINK TO THE TAX RETURN. THE BOARD HAS THE OPPORTUNITY TO REVIEW THE RETURN AND BRING ANY ISSUES TO THE ATTENTION OF THE APPROPRIATE EXECUTIVE MANAGEMENT INDIVIDUALS. A FINAL VERSION OF THE FORM IS APPROVED BY THE CFO AND FILED ELECTRONICALLY BY ERNST YOUNG LLP WITH THE IRS. |
| Form 990, Part VI, Line 12c Conflict of interest policy | DFCI MONITORS AND ENFORCES COMPLIANCE WITH THE DFCI CONFLICT-OF-INTEREST AND CONFIDENTIALITY POLICY FOR BOARD OFFICERS, TRUSTEES, AND KEY EMPLOYEES ("COVERED PERSONS"). THE OFFICE OF THE GENERAL COUNSEL ANNUALLY DISTRIBUTES A CONFLICT OF INTEREST QUESTIONNAIRE AND CONFIDENTIALITY STATEMENT ("STATEMENT") REQUIRING ALL COVERED PERSONS TO DISCLOSE INTERESTS, ROLES, AND ACTIVITIES THAT COULD GIVE RISE TO A POTENTIAL OR ACTUAL CONFLICT WITH THE INTERESTS OF DFCI. IF A TRUSTEE FAILS TO COMPLETE THE ANNUAL STATEMENT. THE CHAIR OF THE GOVERNANCE COMMITTEE MAY TAKE ACTIONS TO SUSPEND THE TRUSTEE. DFCI REQUIRES COVERED PERSONS TO COMPLETE THE STATEMENT UPON INITIAL APPOINTMENT TO A COVERED OFFICE AND TO UPDATE THEIR DISCLOSURES ON A CONTINUING BASIS WHENEVER A COVERED PERSON BECOMES AWARE OF A NEW OR PREVIOUSLY UNDISCLOSED INTEREST. THE OFFICE OF GENERAL COUNSEL COMPARES THE DISCLOSURES TO INSTITUTIONAL INFORMATION IN ORDER TO IDENTIFY POTENTIAL OR ACTUAL CONFLICTS OF INTEREST. THE DFCI GENERAL COUNSEL REPORTS ON ALL DISCLOSURES TO THE DFCI PRESIDENT, CHAIR OF THE DFCI BOARD AND CHAIR OF THE DFCI BOARD GOVERNANCE COMMITTEE. THE BOARD IS RESPONSIBLE UNDER THE COI POLICY FOR ADDRESSING ISSUES RELATED TO CONFLICTS OF COVERED PERSONS. A PROPOSED ARRANGEMENT CREATING A CONFLICT OF INTEREST MAY BE APPROVED IF APPROPRIATE STEPS ARE TAKEN TO ENSURE THAT DFCI MAKES A DECISION IN AN OBJECTIVE AND FAIR MANNER CONSISTENT WITH THE HIGHEST ETHICAL AND LEGAL STANDARDS. SUCH STEPS INCLUDE RECUSAL OF THE COVERED PERSON WITH A CONFLICT OF INTEREST FROM NEGOTIATIONS OR DISCUSSIONS ON BEHALF OF DFCI OR THE ENTITY WITH WHICH DFCI IS DOING BUSINESS AND FROM BOARD OR DFCI MANAGEMENT DISCUSSIONS OF SUCH ARRANGEMENT. |
| Form 990, Part VI, Line 15a Process to establish compensation of top management official | PER DFCI'S EXECUTIVE COMPENSATION PHILOSOPHY, ANNUALLY THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES REVIEWS THE PRESIDENT'S (DFCI'S CHIEF EXECUTIVE OFFICER) PERFORMANCE AND MAKES A RECOMMENDATION REGARDING COMPENSATION TO THE EXECUTIVE COMMITTEE. THE EXECUTIVE COMMITTEE ACTS ON THE RECOMMENDATION. TO ENSURE COMPLIANCE WITH THE PHILOSOPHY, THE COMPENSATION COMMITTEE BI-ANNUALLY COMMISSIONS AN INDEPENDENT REVIEW BY A THIRD-PARTY EXECUTIVE COMPENSATION CONSULTANT TO COMPARE SUCH COMPENSATION WITH THAT OF OTHER SIMILARLY SITUATED INDIVIDUALS IN THE HEALTHCARE FIELD IN AND OUTSIDE OF THE REGION. THE DECISION OF THE EXECUTIVE COMMITTEE IS REPORTED TO THE FULL BOARD. THE BOARD COMPLETED THIS PROCESS AS OF JUNE 2022. |
| Form 990, Part VI, Line 15b Process to establish compensation of other employees | PROCESS FOR DETERMINING COMPENSATION OF OFFICERS AND KEY EMPLOYEES PER DFCI'S EXECUTIVE COMPENSATION PHILOSOPHY, ANNUALLY THE DFCI PRESIDENT REVIEWS THE PERFORMANCE OF OFFICERS AND KEY EMPLOYEES. THE PRESIDENT MAKES A RECOMMENDATION AS TO THE COMPENSATION OF THOSE INDIVIDUALS WHO ARE DISQUALIFIED PERSONS OF DFCI TO THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES. THE COMPENSATION COMMITTEE APPROVES COMPENSATION FOR THOSE INDIVIDUALS BASED ON THAT RECOMMENDATION. FOR KEY EMPLOYEES WHO ARE NOT DISQUALIFIED PERSONS, THE PRESIDENT REPORTS TO THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES ON HER DETERMINATION OF COMPENSATION FOR THOSE INDIVIDUALS. TO ENSURE COMPLIANCE WITH THE PHILOSOPHY, THE PRESIDENT AND COMPENSATION COMMITTEE BIANNUALLY RECEIVE A REPORT BY A THIRD-PARTY EXECUTIVE COMPENSATION CONSULTANT. THE REPORT ANALYZES THE COMPETITIVENESS OF THE TOTAL COMPENSATION PROGRAM FOR DISQUALIFIED PERSONS AGAINST MARKET DATA REPRESENTING DFCI'S LOCAL AND NATIONAL PEER ORGANIZATIONS. THE PRESIDENT MAKES RECOMMENDATIONS FOR MARKET ADJUSTMENTS AS NEEDED FOR THOSE INDIVIDUALS WHO ARE DISQUALIFIED PERSONS OF DFCI TO THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES. THE COMPENSATION COMMITTEE APPROVES MARKET ADJUSTMENTS FOR THOSE INDIVIDUALS BASED ON THE PRESIDENT'S RECOMMENDATION. THE BOARD COMPLETED THIS PROCESS AS OF JUNE 2022. FOR KEY EMPLOYEES WHO ARE NOT DISQUALIFIED PERSONS, THE PRESIDENT REPORTS TO THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES ON HER DETERMINATION OF MARKET ADJUSTMENTS AS NEEDED FOR THOSE INDIVIDUALS. |
| Form 990, Part VI, Line 19 Required documents available to the public | GOVERNING DOCUMENTS THE GOVERNING DOCUMENTS ARE AVAILABLE UPON REQUEST. THE GOVERNING DOCUMENTS ARE ALSO AVAILABLE TO THE PUBLIC ON THE SECRETARY OF THE COMMONWEALTH'S WEBSITE. CONFLICT OF INTEREST POLICY DANA-FARBER CANCER INSTITUTE'S BOARD OF TRUSTEES CONFLICT OF INTEREST POLICY IS AVAILABLE UPON REQUEST. FINANCIAL STATEMENTS THE ORGANIZATION USES THE SERVICES OF DIGITAL ASSURANCE CERTIFICATION LLC (DAC) TO REPORT ANNUAL AUDITED FINANCIAL STATEMENTS AND OTHER RELEVANT ORGANIZATIONAL INFORMATION AS REQUIRED BY CERTAIN REGULATORY AND TAX LAWS. DAC IS A WEBSITE (WWW.DACBOND.COM) FREE TO THE PUBLIC THAT PUBLISHES TAX-EXEMPT BOND ISSUERS' FINANCIAL AND LEGAL DOCUMENTS SUCH AS THE AUDITED FINANCIAL STATEMENTS. FISCAL YEAR 2016 THROUGH THE LATEST ISSUE DATE OF THE AUDITED FINANCIAL STATEMENTS FOR DANA-FARBER CANCER INSTITUTE, INC. CAN BE FOUND ON THE DAC WEBSITE. ANNUAL AUDITED FINANCIAL STATEMENTS FROM FISCAL YEAR 1998 THROUGH FISCAL YEAR 2015 ARE AVAILABLE UPON REQUEST. |
| Form 990, Part VII, Section B, Line 1 | THE AMOUNT PAID TO WALSH BROTHERS, INC. INCLUDED COSTS FOR BUILDING SERVICES AND MATERIALS. HOWEVER, THE ORGANIZATION WAS UNABLE TO OBTAIN INFORMATION TO BREAKOUT THE EXACT AMOUNT FOR MATERIAL COSTS. |
| Form 990, Part VIII, Line 11d Other Miscellaneous Revenue | ALL OTHER - Total Revenue: 2815275, Related or Exempt Function Revenue: , Unrelated Business Revenue: 65661, Revenue Excluded from Tax Under Sections 512, 513, or 514: 2749614; |
| Form 990, Part XI, Line 9 Other changes in net assets or fund balances | CHANGE IN INTEREST IN ASSETS HELD BY AFFILIATES - -XXX-XX-XXXX; CHANGE IN VALUE OF SWAP AGREEMENT - 38290151; PENSION ADJUSTMENT - 4980580; |
| Software ID: | 21014044 |
| Software Version: | 2021v4.2 |